市場調查報告書

復發性、難治性多發性骨髓瘤(RRMM)- 市場洞察,流行病學,市場預測 2028年

Relapsing Refractory Multiple Myeloma - Market Insights, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 911512
出版日期 內容資訊 英文 265 Pages
商品交期: 最快1-2個工作天內
價格
復發性、難治性多發性骨髓瘤(RRMM)- 市場洞察,流行病學,市場預測 2028年 Relapsing Refractory Multiple Myeloma - Market Insights, Epidemiology and Market Forecast - 2028
出版日期: 2019年09月01日內容資訊: 英文 265 Pages
簡介

本報告提供新興10個國家(土耳其、俄羅斯、沙烏地阿拉伯、阿拉伯聯合大公國、墨西哥、哥倫比亞、巴西、阿根廷、中國、台灣)的復發性、難治性多發性骨髓瘤(RRMM)市場調查,市場及疾病概要,性別、選擇藥、各國流行病學的預測,未滿足需求,已上市治療藥及新藥概要,以整體及各國的市場規模的變化與預測,市場成長要素及障礙分析等資料彙整。

目錄

第1章 重要洞察

第2章 復發性、難治性多發性骨髓瘤(RRMM)市場概要

  • 分佈情形(成果值)
  • 分佈情形(預測值)
  • 各地區比較
    • 東亞
    • 中東
    • 東歐
    • 南美

第3章 疾病背景和概要:復發性、難治性多發性骨髓瘤(RRMM)

  • 簡介
  • 症狀
  • 分子分類
  • 分期
  • 診斷
  • 病因
  • 病理生理學
  • 生物標記
  • 患者相關的危險因素
  • 復發性多發性骨髓瘤的治療方法選擇的影響因素
  • 多發性骨髓瘤概要

第4章 流行病學和患者人口

  • 新興10個國家的復發性、難治性多發性骨髓瘤(RRMM)的患者人口

第5章 復發性、難治性多發性骨髓瘤(RRMM)的流行病學:各國

  • 東亞
    • 中國
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數
    • 台灣
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數
  • 中東
    • 沙烏地阿拉伯
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數
    • 阿拉伯聯合大公國
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數
  • 東歐
    • 俄羅斯
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數
    • 土耳其
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數
  • 南美
    • 墨西哥
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數
    • 巴西
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 再復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數
    • 阿根廷
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數
    • 哥倫比亞
      • 多發性骨髓瘤(MM)的診斷罹患數
      • 多發性骨髓瘤(MM)的診斷罹患數:性別
      • 多發性骨髓瘤(MM)的診斷罹患數(第二選擇藥)
      • 多發性骨髓瘤(MM)的診斷罹患數(第三選擇藥)
      • 復發性、難治性多發性骨髓瘤(RRMM)的診斷罹患數

第6章 治療

  • 化療
  • 蛋白梅體抑制劑
  • 免疫調節劑
  • 單株抗體
  • RRMM的治療
    • 支持療法
    • 併發症管理(CRAB以及其他)
    • 治療中/治療後監測
    • 復發治療
  • 管理

第7章 治療流程

第8章 未滿足需求

第9章 已上市治療藥

  • Pomalyst/Imnovid:Celgene
    • 醫藥品概要
    • 法規的里程碑
    • 其他開發趨勢
    • 安全性和有效性
    • 開發平台活動
    • 產品簡介
  • Revlimid (Lenalidomide):Celgene
  • Empliciti (Elotuzumab):Bristol-Myers Squibb
  • Thalomid (Thalidomide):Celgene
  • Darzalex:Janssen Biotech
  • Kyprolis:Amgen
  • Velcade:Millennium Pharmaceuticals(武田藥品工業)
  • Mozobil:Genzyme

第10章 新藥

  • Key Cross Competition
  • Melflufen:Oncopeptides
    • 醫藥品概要
    • 其他開發趨勢
    • 臨床開發
    • 產品簡介
  • Idecabtagene vicleucel(bb2121):Celgene / Bluebird Bio
  • Isatuximab:Sanofi
  • LCAR-B38M BCMA CAR-T Therapy (JNJ-68284528):Legend Biotech Biotech/Janssen Biotech
  • Belantamab Mafodotin:GlaxoSmithKline
  • Ibrutinib:Pharmacyclics
  • Xpovio:Karyopharm Therapeutics

第11章 新興10個國家的復發性、難治性多發性骨髓瘤(RRMM)市場分析

  • 主要調查結果
  • 新興10個國家的市場規模分析

第12章 市場預測

  • 專家的意見
  • 東亞
    • 中國的市場規模
    • 台灣的市場規模
  • 中東
    • 沙烏地阿拉伯的市場規模
    • 阿拉伯聯合大公國的市場規模
  • 東歐
    • 俄羅斯的市場規模
    • 土耳其的市場規模
  • 南美
    • 墨西哥的市場規模
    • 巴西的市場規模
    • 阿根廷的市場規模
    • 哥倫比亞的市場規模

第13章 市場成長要素

第14章 市場障礙

第15章 附錄

  • 報告方法

第16章 DelveInsight的服務內容

第17章 免責聲明

第18章 關於DelveInsight

目錄
Product Code: DIMI0677

DelveInsight's 'Relapsing Refractory Multiple Myeloma- Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Relapsing Refractory Multiple Myeloma in Asia (China and Taiwan), Middle East (Saudi Arabia and UAE), Eastern Europe (Russia and Turkey) and LATAM (Mexico, Brazil, Argentina and Columbia).

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Relapsing Refractory Multiple Myeloma from 2017 to 2028 segmented by ten emerging markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • Asia (China and Taiwan)
  • Middle East (Saudi Arabia and UAE)
  • Eastern Europe (Russia and Turkey)
  • LATAM (Mexico, Brazil, Argentina and Columbia)

Study Period: 2017-2028

Relapsing Refractory Multiple Myeloma - Disease Understanding and Treatment Algorithm

Multiple Myeloma (MM) is the second most incident hematological malignancy worldwide, with a median onset of 60 years. This incurable malignancy develops from an accumulation of terminally differentiated monoclonal plasma cells (PC) in the bone marrow. The mechanism of action of MM characterized by the unusual increase of monoclonal paraprotein leading to evidence of specific end-organ damage. The majority of patients with multiple myeloma (MM) will have an initial response to treatment with modern combination regimens. However, conventional therapy is not curative and most of these patients will ultimately progress. In addition, some patients will not respond to initial treatment (i.e., refractory disease). Relapsed or refractory MM is usually identified through routine monitoring with laboratory studies. The signs and symptoms of Multiple Myeloma include hypercalcemia, renal insufficiency, anemia, lytic bony lesions along with a monoclonal protein in the serum, increase in the number of clonal plasma cells in the bone marrow, etc.

The DelveInsight Relapsing Refractory Multiple Myeloma market report gives the thorough understanding of the Relapsing Refractory Multiple Myeloma by including details such as disease introduction, symptoms of multiple myeloma, molecular classification of Multiple Myeloma, stages of multiple myeloma, pathogenesis, pathophysiology, biomarkers for multiple myeloma, diagnosis and patient-related risk factors.

Relapsing Refractory Multiple Myeloma Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Relapsing Refractory Multiple Myeloma in 10 EM covering Asia (China and Taiwan), Middle East (Saudi Arabia and UAE), Eastern Europe (Russia and Turkey) and LATAM (Mexico, Brazil, Argentina and Columbia) from 2017-2028 for the following aspects:

  • Diagnosed Incident cases of Multiple Myeloma (MM)
  • Gender-specific Diagnosed Incidence of Multiple Myeloma (MM)
  • Diagnosed Incident Multiple Myeloma (MM) Population on Second Line of Treatment
  • Diagnosed Incident Multiple Myeloma (MM) Population on Third Line (and above) of Treatment
  • Total Diagnosed Incident RRMM cases

There are several potential research papers and studies evaluated in order to analyze the overall epidemiology trend in the emerging markets. Few are listed below:

Lu et al. conducted a study "Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis" with the aim to understand the clinical features and treatment outcome of Chinese patients with multiple myeloma (MM). As per the study, if the Japanese incidence of MM is applied to China, there would be an estimated 27,800 new cases (1.39 billion × 2 per 100,000) each year and a total of 200,000 cases in China. With the acceleration of the aging process in China, it is predicted that MM, with rapid growth in incidence, will become one of the more significant diseases that affect people's health in the country. It has also been reported that immigrants from Asia living in the USA have an increased incidence of MM compared with those living in Asia.

Hungria et al. suggest that Multiple Myeloma (MM) is a disorder characterized by abnormal clonal proliferation of plasmocytes in the bone marrow resulting in the production of monoclonal immunoglobulins associated with organic disorders. MM accounts for 1% of all neoplastic diseases and 13% of hematologic neoplasms as stated in "Guidelines on the diagnosis and management of multiple myeloma treatment: Associacao Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associacao Medica Brasileira - 2012." In Brazil, there is no exact knowledge of the incidence of this disease.

Relapsing Refractory Multiple Myeloma Drug Chapters

This segment of the Relapsing Refractory Multiple Myeloma report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

To meet the increasing demand for the treatment of Relapsing Refractory Multiple Myeloma, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of Relapsing Refractory Multiple Myeloma & awareness of the disease. The overall dynamics of Relapsing Refractory Multiple Myeloma market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Oncopeptides, Celgene/Bluebird Bio, Sanofi, Legend Biotech Biotech/Janssen Biotech, GlaxoSmithKline, Pharmacyclics and Karyopharm Therapeutics will significantly increase the market during the forecast period (2019-2028).

Relapsing Refractory Multiple Myeloma Market Outlook

Multiple Myeloma (MM) is a blood cancer affecting plasma cells. The malignant plasma cells show metastases aggravating the problem. In some cases, cancer returns after the treatment or after a period of remission. Most of the patients relapse at some point due to lack of specific cure. Adding worries to myeloma condition, some patients do not respond to the therapy (or sometimes respond to initial treatment, but not to the treatment following a relapse) thereby becoming refractory, and hence known as Relapsing Refractory Multiple Myeloma (RRMM).

The market holds a diverse range of therapeutic alternatives for treatment, including Proteasome Inhibitors, Immunomodulating Agents, Histone Deacetylase (HDAC) inhibitors, Monoclonal Antibodies, Chemotherapy, Corticosteroids, and Nuclear export inhibitors in different lines of treatment. The treatment pattern lays more focus on second line of therapy and above for RRMM. Proteasome Inhibitors (PIs) forms a widely used class for treatment, including Bortezomib (Velcade), Carfilzomib (Kyprolis), and Ixazomib (Ninlaro). Proteasome inhibitors work by inhibiting enzyme complexes (proteasomes) in cells from breaking down proteins important for controlling cell division. PIs affect tumor cells more than normal cells but also accompanies few side effects. The next in the list is Immunomodulators (IMiDs), including Thalidomide (Thalomid), Lenalidomide (Revlimid), and Pomalidomide (Pomalyst/Imnovid). IMiDs possess pleiotropic anti-myeloma properties, including immune-modulation, anti-angiogenic, anti-inflammatory, and anti-proliferative effects. IMiDs can increase the blood-clotting risk, thereby often given along with aspirin or a blood thinner. The treatment regime also includes Histone Deactylase (HDAC) Inhibitors affecting active genes or by interacting with proteins in chromosomes called histones. Panobinostat (Farydak) is an HDAC inhibitor used to treat patients who have already been treated with bortezomib and an immunomodulating agent. Monoclonal Antibodies have gained great popularity for the treatment of myeloma. Antibodies are proteins made by the body's immune system to help fight infections. Man-made versions (monoclonal antibodies), can be designed to attack a specific target, such as proteins on the surface of myeloma cells. mAbs used for the treatment of RRMM include Daratumumab (Darzalex) and Elotuzumab (Empliciti). The other treatment alternatives comprise Chemotherapy drugs and Corticosteroids.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Relapsing Refractory Multiple Myeloma in 10 EM is expected to change from 2019-2028.

Relapsing Refractory Multiple Myeloma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of therapies for Relapsing Refractory Multiple Myeloma such as Melflufen (Oncopeptides), Idecabtagene vicleucel (Celgene/Bluebird), Isatuximab (Sanofi), JNJ-68284528 (Legend Biotech Biotech/Janssen Biotech), GSK2857916 (GlaxoSmithKline), Ibrutinib (Pharmacyclics) and Xpovio (Karyopharm Therapeutics) targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Relapsing Refractory Multiple Myeloma market. Although approved only in the United States, the drug has not been launched in the emerging markets, therefore considered as an emerging therapy in this region.

Relapsing Refractory Multiple Myeloma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Relapsing Refractory Multiple Myeloma Report Key Strengths

  • 10 Year Forecast
  • 10 EM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Relapsing Refractory Multiple Myeloma Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Relapsing Refractory Multiple Myeloma market
  • Organize sales and marketing efforts by identifying the best opportunities for Relapsing Refractory Multiple Myeloma market
  • To understand the future market competition in the Relapsing Refractory Multiple Myeloma market.

Table of Contents

1. Key Insights

2. Relapsing Refractory Multiple Myeloma Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Relapsing Refractory Multiple Myeloma in 2017
  • 2.2. Market Share (%) Distribution of Relapsing Refractory Multiple Myeloma in 2028
  • 2.3. Region-Wise Comparison of Market Share
    • 2.3.1. East Asia
    • 2.3.2. Middle East
    • 2.3.3. Eastern Europe
    • 2.3.4. Latin America

3. Disease Background and Overview: Relapsing Refractory Multiple Myeloma (RRMM)

  • 3.1. Introduction
  • 3.2. Symptoms of multiple myeloma
  • 3.3. Molecular Classification of Multiple Myeloma
  • 3.4. Stages of Multiple Myeloma
  • 3.5. Diagnosis of Multiple Myeloma
  • 3.6. Pathogenesis of Multiple Myeloma
    • 3.6.1. Molecular mechanisms underlying the progression of multiple myeloma
    • 3.6.2. Molecular pathogenesis of multiple myeloma and its premalignant precursor
  • 3.7. Pathophysiology of Multiple Myeloma
  • 3.8. Biomarkers for Multiple Myeloma
    • 3.8.1. Serum M-protein and light chains as biomarkers
    • 3.8.2. Potential proteomic biomarkers
    • 3.8.3. Cytogenetic biomarkers in multiple myeloma
  • 3.9. Patient-related risk factors
  • 3.10. Factors influencing the choice of therapy at relapse
  • 3.11. Nutshell of Multiple Myeloma

4. Epidemiology and Patient Population: Key Findings

  • 4.1. 10 EM Total Diagnosed Incident Patient Population of Relapsing Refractory Multiple Myeloma

5. Country Wise-Epidemiology of Relapsing Refractory Multiple Myeloma

  • 5.1. East Asia: China and Taiwan
    • 5.1.1. Assumptions and Rationale
  • 5.2. China
    • 5.2.1. Multiple Myeloma (MM) Diagnosed Incident cases in China
    • 5.2.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in China
    • 5.2.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in China
    • 5.2.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in China
    • 5.2.5. RRMM Total Diagnosed Incident cases in China
  • 5.3. Taiwan
    • 5.3.1. Multiple Myeloma (MM) Diagnosed Incident cases in Taiwan
    • 5.3.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Taiwan
    • 5.3.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Taiwan
    • 5.3.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Taiwan
    • 5.3.5. RRMM Total Diagnosed Incident cases in Taiwan
  • 5.4. Middle East: Saudi Arabia and United Arab Emirates
    • 5.4.1. Assumptions and Rationale
  • 5.5. Saudi Arabia
    • 5.5.1. Multiple Myeloma (MM) Diagnosed Incident cases in Saudi Arabia
    • 5.5.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Saudi Arabia
    • 5.5.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Saudi Arabia
    • 5.5.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Saudi Arabia
    • 5.5.5. RRMM Total Diagnosed Incident cases in Saudi Arabia
  • 5.6. United Arab Emirates
    • 5.6.1. Multiple Myeloma (MM) Diagnosed Incident cases in United Arab Emirates
    • 5.6.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in United Arab Emirates
    • 5.6.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in United Arab Emirates
    • 5.6.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in United Arab Emirates
    • 5.6.5. RRMM Total Diagnosed Incident cases in United Arab Emirates
  • 5.7. Eastern Europe: Russia and Turkey
    • 5.7.1. Assumptions and Rationale
  • 5.8. Russia
    • 5.8.1. Multiple Myeloma (MM) Diagnosed Incident cases in Russia
    • 5.8.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Russia
    • 5.8.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Russia
    • 5.8.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Russia
    • 5.8.5. RRMM Total Diagnosed Incident cases in Russia
  • 5.9. Turkey
    • 5.9.1. Multiple Myeloma (MM) Diagnosed Incident cases in Turkey
    • 5.9.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Turkey
    • 5.9.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Turkey
    • 5.9.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Turkey
    • 5.9.5. RRMM Total Diagnosed Incident cases in Turkey
  • 5.10. Latin America (LATAM): Argentina, Brazil, Colombia, Mexico
    • 5.10.1. Assumptions and Rationale
  • 5.11. Mexico
    • 5.11.1. Multiple Myeloma (MM) Diagnosed Incident cases in Mexico
    • 5.11.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Mexico
    • 5.11.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Mexico
    • 5.11.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Mexico
    • 5.11.5. RRMM Total Diagnosed Incident cases in Mexico
  • 5.12. Brazil
    • 5.12.1. Multiple Myeloma (MM) Diagnosed Incident cases in Brazil
    • 5.12.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Brazil
    • 5.12.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Brazil
    • 5.12.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Brazil
    • 5.12.5. RRMM Total Diagnosed Incident cases in Brazil
  • 5.13. Argentina
    • 5.13.1. Multiple Myeloma (MM) Diagnosed Incident cases in Argentina
    • 5.13.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Argentina
    • 5.13.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Argentina
    • 5.13.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Argentina
    • 5.13.5. RRMM Total Diagnosed Incident cases in Argentina
  • 5.14. Colombia
    • 5.14.1. Multiple Myeloma (MM) Diagnosed Incident cases in Colombia
    • 5.14.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Colombia
    • 5.14.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Colombia
    • 5.14.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Colombia
    • 5.14.5. RRMM Total Diagnosed Incident cases in Colombia

6. Treatment

  • 6.1. Chemotherapy
  • 6.2. Proteasome inhibitors
  • 6.3. Immunomodulatory Agents
  • 6.4. Monoclonal Antibodies
  • 6.5. For Refractory/Relapsed Disease
    • 6.5.1. Supportive care
    • 6.5.2. Management of complications (CRAB and others)
    • 6.5.3. Monitoring during and after therapy
    • 6.5.4. Treatment of recurrences
  • 6.6. Management

7. Treatment Algorithm

8. Unmet needs

9. Marketed Drugs

  • 9.1. Pomalyst/Imnovid: Celgene
    • 9.1.1. Drug Description
    • 9.1.2. Regulatory Milestones
    • 9.1.3. Other Development Activities
    • 9.1.4. Safety and Efficacy
    • 9.1.5. Pipeline Activity
    • 9.1.6. Product Profile
  • 9.2. Revlimid (Lenalidomide): Celgene
    • 9.2.1. Drug Description
    • 9.2.2. Regulatory Milestones
    • 9.2.3. Other Development Activities
    • 9.2.4. Safety and Efficacy
    • 9.2.5. Pipeline Activity
    • 9.2.6. Product Profile
  • 9.3. Empliciti (Elotuzumab): Bristol-Myers Squibb
    • 9.3.1. Drug Description
    • 9.3.2. Regulatory Milestones
    • 9.3.3. Other Development Activities
    • 9.3.4. Safety and Efficacy
    • 9.3.5. Product Profile
  • 9.4. Thalomid (Thalidomide): Celgene
    • 9.4.1. Drug Description
    • 9.4.2. Regulatory Milestones
    • 9.4.3. Other Development Activities
    • 9.4.4. Safety and Efficacy
    • 9.4.5. Product Profile
  • 9.5. Darzalex: Janssen Biotech
    • 9.5.1. Drug Description
    • 9.5.2. Regulatory Milestones
    • 9.5.3. Other Development Activities
    • 9.5.4. Safety and Efficacy
    • 9.5.5. Pipeline Activity
    • 9.5.6. Product Profile
  • 9.6. Kyprolis: Amgen
    • 9.6.1. Drug Description
    • 9.6.2. Regulatory Milestones
    • 9.6.3. Other Development Activities
    • 9.6.4. Safety and Efficacy
    • 9.6.5. Pipeline Activity
    • 9.6.6. Product Profile
  • 9.7. Velcade: Millennium Pharmaceuticals (Takeda)
    • 9.7.1. Drug Description
    • 9.7.2. Regulatory Milestones
    • 9.7.3. Other Development Activities
    • 9.7.4. Safety and Efficacy
    • 9.7.5. Post-marketing study
    • 9.7.6. Product Profile
  • 9.8. Mozobil: Genzyme
    • 9.8.1. Drug Description
    • 9.8.2. Regulatory Milestones
    • 9.8.3. Other Development Activities
    • 9.8.4. Safety and Efficacy
    • 9.8.5. Product Profile

10. Emerging Drugs

  • 10.1. Key Cross Competition
  • 10.2. Melflufen: Oncopeptides
    • 10.2.1. Product Description
    • 10.2.2. Other Developmental Activities
    • 10.2.3. Clinical Development
    • 10.2.4. Product Profile
  • 10.3. Idecabtagene vicleucel (bb2121): Celgene/Bluebird Bio
    • 10.3.1. Product Description
    • 10.3.2. Other Developmental Activities
    • 10.3.3. Clinical Development
    • 10.3.4. Product Profile
  • 10.4. Isatuximab: Sanofi
    • 10.4.1. Product Description
    • 10.4.2. Other Developmental Activities
    • 10.4.3. Clinical Development
    • 10.4.4. Product Profile
  • 10.5. LCAR-B38M BCMA CAR-T Therapy (JNJ-68284528): Legend Biotech Biotech/Janssen Biotech
    • 10.5.1. Product Description
    • 10.5.2. Other Developmental Activities
    • 10.5.3. Clinical Development
    • 10.5.4. Product Profile
  • 10.6. Belantamab mafodotin (GSK2857916): GlaxoSmithKline
    • 10.6.1. Product Description
    • 10.6.2. Other Developmental Activities
    • 10.6.3. Clinical Development
    • 10.6.4. Product Profile
  • 10.7. Ibrutinib: Pharmacyclics
    • 10.7.1. Product Description
    • 10.7.2. Other Developmental Activities
    • 10.7.3. Clinical Development
    • 10.7.4. Product Profile
  • 10.8. Xpovio: Karyopharm Therapeutics
    • 10.8.1. Drug Description
    • 10.8.2. Regulatory Milestones
    • 10.8.3. Other Development Activities
    • 10.8.4. Safety and Efficacy
    • 10.8.5. Pipeline Activity
    • 10.8.6. Product Profile

11. Relapsing Refractory Multiple Myeloma: 10 Emerging Market (EM) Analysis

  • 11.1. Key Findings
  • 11.2. Market Size of Relapsing Refractory Multiple Myeloma in 10 EM

12. Market Outlook

  • 12.1. What do Experts say??
  • 12.2. East Asia: China and Taiwan
    • 12.2.1. China Market Size
      • 12.2.1.1. Total Market size of Relapsing Refractory Multiple Myeloma
      • 12.2.1.2. Current Market Size by Therapies
      • 12.2.1.3. Emerging Market Size by Therapies
    • 12.2.2. Taiwan Market Size
      • 12.2.2.1. Total Market size of Relapsing Refractory Multiple Myeloma
      • 12.2.2.2. Current Market Size by Therapies
      • 12.2.2.3. Emerging Market Size by Therapies
  • 12.3. Middle East: Saudi Arabia and the United Arab Emirates
    • 12.3.1. Saudi Arabia Market Size
      • 12.3.1.1. Total Market size of Relapsing Refractory Multiple Myeloma
      • 12.3.1.2. Current Market Size by Therapies
      • 12.3.1.3. Emerging Market Size by Therapies
    • 12.3.2. United Arab Emirates Market Size
      • 12.3.2.1. Total Market size of Relapsing Refractory Multiple Myeloma
      • 12.3.2.2. Current Market Size by Therapies
      • 12.3.2.3. Emerging Market Size by Therapies
  • 12.4. Eastern Europe: Russia and Turkey
    • 12.4.1. Russia Market Size
      • 12.4.1.1. Total Market size of Relapsing Refractory Multiple Myeloma
      • 12.4.1.2. Current Market Size by Therapies
      • 12.4.1.3. Emerging Market Size by Therapies
    • 12.4.2. Turkey Market Size
      • 12.4.2.1. Total Market size of Relapsing Refractory Multiple Myeloma
      • 12.4.2.2. Current Market Size by Therapies
      • 12.4.2.3. Emerging Market Size by Therapies
  • 12.5. Latin America (LATAM): Argentina, Brazil, Colombia, Mexico
    • 12.5.1. Mexico Market Size
      • 12.5.1.1. Total Market size of Relapsing Refractory Multiple Myeloma
      • 12.5.1.2. Current Market Size by Therapies
      • 12.5.1.3. Emerging Market Size by Therapies
    • 12.5.2. Brazil Market Size
      • 12.5.2.1. Total Market size of Relapsing Refractory Multiple Myeloma
      • 12.5.2.2. Current Market Size by Therapies
      • 12.5.2.3. Emerging Market Size by Therapies
    • 12.5.3. Argentina Market Size
      • 12.5.3.1. Total Market size of Relapsing Refractory Multiple Myeloma
      • 12.5.3.2. Current Market Size by Therapies
      • 12.5.3.3. Emerging Market Size by Therapies
    • 12.5.4. Colombia Market Size
      • 12.5.4.1. Total Market size of Relapsing Refractory Multiple Myeloma
      • 12.5.4.2. Current Market Size by Therapies
      • 12.5.4.3. Emerging Market Size by Therapies

13. Market Drivers

14. Market Barriers

15. Appendix

  • 15.1. Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

List of Tables

Table 1 Primary molecular cytogenetic classification of multiple myeloma

Table 2 Staging systems and prognostic markers in patients with multiple myeloma (survival times are according to the ISS)

Table 3 Disease definitions for the monoclonal gammopathies: MGUS and related disorders

Table 4 Total Diagnosed Incident Patient Population of Relapsing Refractory Multiple Myeloma in 10 EM Countries (2017-2028)

Table 5 Multiple Myeloma (MM) Diagnosed Incident cases in China (2017-2028)

Table 6 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in China (2017-2028)

Table 7 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in China (2017-2028)

Table 8 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in China (2017-2028)

Table 9 RRMM Total Diagnosed Incident cases in China (2017-2028)

Table 10 Multiple Myeloma (MM) Diagnosed Incident cases in Taiwan (2017-2028)

Table 11 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Taiwan (2017-2028)

Table 12 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Taiwan (2017-2028)

Table 13 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Taiwan (2017-2028)

Table 14 RRMM Total Diagnosed Incident cases in Taiwan (2017-2028)

Table 15 Multiple Myeloma (MM) Diagnosed Incident cases in Saudi Arabia (2017-2028)

Table 16 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Saudi Arabia (2017-2028)

Table 17 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Saudi Arabia (2017-2028)

Table 18 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Saudi Arabia (2017-2028)

Table 19 RRMM Total Diagnosed Incident cases in Saudi Arabia (2017-2028)

Table 20 Multiple Myeloma (MM) Diagnosed Incident cases in United Arab Emirates (2017-2028)

Table 21 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in United Arab Emirates (2017-2028)

Table 22 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in United Arab Emirates (2017-2028)

Table 23 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in United Arab Emirates (2017-2028)

Table 24 RRMM Total Diagnosed Incident cases in United Arab Emirates (2017-2028)

Table 25 Multiple Myeloma (MM) Diagnosed Incident cases in Russia (2017-2028)

Table 26 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Russia (2017-2028)

Table 27 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Russia (2017-2028)

Table 28 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Russia (2017-2028)

Table 29 RRMM Total Diagnosed Incident cases in Russia (2017-2028)

Table 30 Multiple Myeloma (MM) Diagnosed Incident cases in Turkey (2017-2028)

Table 31 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Turkey (2017-2028)

Table 32 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Turkey (2017-2028)

Table 33 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Turkey (2017-2028)

Table 34 RRMM Total Diagnosed Incident cases in Turkey (2017-2028)

Table 35 Multiple Myeloma (MM) Diagnosed Incident cases in Mexico (2017-2028)

Table 36 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Mexico (2017-2028)

Table 37 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Mexico (2017-2028)

  • Table 38: Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Mexico (2017-2028)

Table 39 RRMM Total Diagnosed Incident cases in Turkey in Mexico (2017-2028)

Table 40 Multiple Myeloma (MM) Diagnosed Incident cases in Brazil (2017-2028)

Table 41 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Brazil (2017-2028)

Table 42 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Brazil (2017-2028)

Table 43 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Brazil (2017-2028)

Table 44 RRMM Total Diagnosed Incident cases in Brazil (2017-2028)

Table 45 Multiple Myeloma (MM) Diagnosed Incident cases in Argentina (2017-2028)

Table 46 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Argentina (2017-2028)

Table 47 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Argentina (2017-2028)

Table 48 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Argentina (2017-2028)

Table 49 RRMM Total Diagnosed Incident cases in Argentina (2017-2028)

Table 50 Multiple Myeloma (MM) Diagnosed Incident cases in Colombia (2017-2028)

Table 51 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Colombia (2017-2028)

Table 52 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Colombia (2017-2028)

Table 53 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Colombia (2017-2028)

Table 54 RRMM Total Diagnosed Incident cases in Colombia (2017-2028)

Table 55 Comparison of Phase III Emerging Drugs Under Development

Table 56 Melflufen, Clinical Trial Description

Table 57 Idecabtagene vicleucel, Clinical Trial Description

Table 58 Isatuximab, Clinical Trial Description

Table 59 LCAR-B38M CAR-T Cell (JNJ-68284528), Clinical Trial Description

Table 60 Belantamab mafodotin (GSK2857916), Clinical Trial Description

Table 61 Ibrutinib, Clinical Trial Description

Table 62 10 Emerging Market Size of Relapsing Refractory Multiple Myeloma in USD Million (2017-2028)

Table 63 Market Size of China for Relapsing Refractory Multiple Myeloma, USD Million (2017-2028)

Table 64 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in China, in USD Million (2017-2028)

Table 65 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in China, in USD Million (2017-2028)

Table 66 Market Size of Taiwan for Relapsing Refractory Multiple Myeloma, USD Million (2017-2028)

Table 67 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in Taiwan, in USD Million (2017-2028)

Table 68 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in Taiwan, in USD Million (2017-2028)

Table 69 Market Size of Saudi Arabia for Relapsing Refractory Multiple Myeloma, USD Million (2017-2028)

Table 70 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in Saudi Arabia, in USD Million (2017-2028)

Table 71 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in Saudi Arabia, in USD Million (2017-2028)

Table 72 Market Size of United Arab Emirates for Relapsing Refractory Multiple Myeloma, USD Million (2017-2028)

Table 73 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in United Arab Emirates, in USD Million (2017-2028)

Table 74 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in United Arab Emirates, in USD Million (2017-2028)

Table 75 Market Size of Russia for Relapsing Refractory Multiple Myeloma, USD Million (2017-2028)

Table 76 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in Russia, in USD Million (2017-2028)

Table 77 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in Russia, in USD Million (2017-2028)

Table 78 Market Size of Turkey for Relapsing Refractory Multiple Myeloma, USD Million (2017-2028)

Table 79 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in Turkey, in USD Million (2017-2028)

Table 80 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in Turkey, in USD Million (2017-2028)

Table 81 Market Size of Mexico for Relapsing Refractory Multiple Myeloma, USD Million (2017-2028)

Table 82 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in Mexico, in USD Million (2017-2028)

Table 83 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in Mexico, in USD Million (2017-2028)

Table 84 Market Size of Brazil for Relapsing Refractory Multiple Myeloma, USD Million (2017-2028)

Table 85 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in Brazil, in USD Million (2017-2028)

Table 86 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in Brazil, in USD Million (2017-2028)

Table 87 Market Size of Argentina for Relapsing Refractory Multiple Myeloma, USD Million (2017-2028)

Table 88 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in Argentina, in USD Million (2017-2028)

Table 89 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in Argentina, in USD Million (2017-2028)

Table 90 Market Size of Colombia for Relapsing Refractory Multiple Myeloma, USD Million (2017-2028)

Table 91 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in Colombia, in USD Million (2017-2028)

Table 92 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in Colombia, in USD Million (2017-2028)

List of Figures

Figure 1 Interactions of MM tumor cells with the BM microenvironment. Five kinds of cells in the BM microenvironment are depicted, as well as a few of the complex interactions among these cells and MM cells.

Figure 2 Interaction of multiple myeloma cells in their bone marrow milieu

Figure 3 Technological advances in detecting biomarkers in multiple myeloma.

Figure 4 Factors influencing the choice of therapy at relapse

Figure 5 Total Diagnosed Incident Patient Population of Relapsing Refractory Multiple Myeloma in 10 EM Countries (2017-2028)

Figure 6 Multiple Myeloma (MM) Diagnosed Incident cases in China (2017-2028)

Figure 7 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in China (2017-2028)

Figure 8 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in China (2017-2028)

Figure 9 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in China (2017-2028)

Figure 10 RRMM Total Diagnosed Incident cases in China (2017-2028)

Figure 11 Multiple Myeloma (MM) Diagnosed Incident cases in Taiwan (2017-2028)

Figure 12 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Taiwan (2017-2028)

Figure 13 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Taiwan (2017-2028)

Figure 14 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Taiwan (2017-2028)

Figure 15 RRMM Total Diagnosed Incident cases in Taiwan (2017-2028)

Figure 16 Multiple Myeloma (MM) Diagnosed Incident cases in Saudi Arabia (2017-2028)

Figure 17 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Saudi Arabia (2017-2028)

Figure 18 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Saudi Arabia (2017-2028)

Figure 19 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Saudi Arabia (2017-2028)

Figure 20 RRMM Total Diagnosed Incident cases in Saudi Arabia (2017-2028)

Figure 21 Multiple Myeloma (MM) Diagnosed Incident cases in United Arab Emirates (2017-2028)

Figure 22 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in United Arab Emirates (2017-2028)

Figure 23 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in United Arab Emirates (2017-2028)

Figure 24 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in United Arab Emirates (2017-2028)

Figure 25 RRMM Total Diagnosed Incident cases in United Arab Emirates (2017-2028)

Figure 26 Multiple Myeloma (MM) Diagnosed Incident cases in Russia (2017-2028)

Figure 27 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Russia (2017-2028)

Figure 28 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Russia (2017-2028)

Figure 29 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Russia (2017-2028)

Figure 30 RRMM Total Diagnosed Incident cases in Russia (2017-2028)

Figure 31 Multiple Myeloma (MM) Diagnosed Incident cases in Turkey (2017-2028)

Figure 32 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Turkey (2017-2028)

Figure 33 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Turkey (2017-2028)

Figure 34 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Turkey (2017-2028)

Figure 35 RRMM Total Diagnosed Incident cases in Turkey (2017-2028)

Figure 36 Multiple Myeloma (MM) Diagnosed Incident cases in Mexico (2017-2028)

Figure 37 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Mexico (2017-2028)

Figure 38 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Mexico (2017-2028)

Figure 39 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Mexico (2017-2028)

Figure 40 RRMM Total Diagnosed Incident cases in Turkey in Mexico (2017-2028)

Figure 41 Multiple Myeloma (MM) Diagnosed Incident cases in Brazil (2017-2028)

Figure 42 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Brazil (2017-2028)

Figure 43 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Brazil (2017-2028)

Figure 44 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Brazil (2017-2028)

Figure 45 RRMM Total Diagnosed Incident cases in Brazil (2017-2028)

Figure 46 Multiple Myeloma (MM) Diagnosed Incident cases in Argentina (2017-2028)

Figure 47 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Argentina (2017-2028)

Figure 48 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Argentina (2017-2028)

Figure 49 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Argentina (2017-2028)

Figure 50 RRMM Total Diagnosed Incident cases in Argentina (2017-2028)

Figure 51 Multiple Myeloma (MM) Diagnosed Incident cases in Colombia (2017-2028)

Figure 52 Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Colombia (2017-2028)

Figure 53 Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Colombia (2017-2028)

Figure 54 Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Colombia (2017-2028)

Figure 55 RRMM Total Diagnosed Incident cases in Colombia (2017-2028)

Figure 56 Treatment algorithm for Relapsing Refractory Multiple Myeloma

Figure 57 Unmet Needs of Relapsing Refractory Multiple Myeloma

Figure 58 10 Emerging Market Size of Relapsing Refractory Multiple Myeloma in USD Million (2017-2028)

Figure 59 Market Size of Relapsing Refractory Multiple Myeloma in China, USD Millions (2017-2028)

Figure 60 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in China, in USD Million (2017-2028)

Figure 61 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in China, in USD Million (2017-2028)

Figure 62 Market Size of Relapsing Refractory Multiple Myeloma in Taiwan, USD Millions (2017-2028)

Figure 63 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in Taiwan, in USD Million (2017-2028)

Figure 64 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in Taiwan, in USD Million (2017-2028)

Figure 65 Market Size of Relapsing Refractory Multiple Myeloma in Saudi Arabia, USD Millions (2017-2028)

Figure 66 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in Saudi Arabia, in USD Million (2017-2028)

Figure 67 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in Saudi Arabia, in USD Million (2017-2028)

Figure 68 Market Size of Relapsing Refractory Multiple Myeloma in United Arab Emirates, USD Millions (2017-2028)

Figure 69 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in United Arab Emirates, in USD Million (2017-2028)

Figure 70 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in United Arab Emirates, in USD Million (2017-2028)

Figure 71 Market Size of Relapsing Refractory Multiple Myeloma in Russia, USD Millions (2017-2028)

Figure 72 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in Russia, in USD Million (2017-2028)

Figure 73 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in Russia, in USD Million (2017-2028)

Figure 74 Market Size of Relapsing Refractory Multiple Myeloma in Turkey, USD Millions (2017-2028)

Figure 75 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in Turkey, in USD Million (2017-2028)

Figure 76 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in Turkey, in USD Million (2017-2028)

Figure 77 Market Size of Relapsing Refractory Multiple Myeloma in Mexico, USD Millions (2017-2028)

Figure 78 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in Mexico, in USD Million (2017-2028)

Figure 79 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in Mexico, in USD Million (2017-2028)

Figure 80 Market Size of Relapsing Refractory Multiple Myeloma in Brazil, USD Millions (2017-2028)

Figure 81 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in Brazil, in USD Million (2017-2028)

Figure 82 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in Brazil, in USD Million (2017-2028)

Figure 83 Market Size of Relapsing Refractory Multiple Myeloma in Argentina, USD Millions (2017-2028)

Figure 84 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in Argentina, in USD Million (2017-2028)

Figure 85 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in Argentina, in USD Million (2017-2028)

Figure 86 Market Size of Relapsing Refractory Multiple Myeloma in Colombia, USD Millions (2017-2028)

Figure 87 Current Market size of Relapsing Refractory Multiple Myeloma by therapies in Colombia, in USD Million (2017-2028)

Figure 88 Emerging Market size of Relapsing Refractory Multiple Myeloma by therapies in Colombia, in USD Million (2017-2028)

Figure 89 Market Drivers

Figure 90 Market Barriers